Prospective Evaluation of Proteinuria and Renal Function in Non-diabetic Patients With Progressive Renal Disease (PLANET II)

AstraZeneca

Status and phase: Completed; Phase 2

Conditions: Hyperlipidemia

Treatments: Drug: Atorvastatin; Drug: Rosuvastatin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00296400

D3569C00011

PLANET II

Details and patient eligibility

About

The purpose of this study is to evaluate the effects of Crestor (rosuvastatin) and (Lipitor) atorvastatin on urinary protein excretion over 1 year in non-diabetes with moderate proteinuria and hypercholesterolaemia.

Enrollment: 237 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• greater than or equal to 18 years of age
• Hyperlipidemia
• Urinary protein

Exclusion criteria

• Previous rosuvastatin treatment < 6 months prior to Visit 1
• Statin intolerance
• Severe hypertension
• Diabetes

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind